Catarina Edfjäll
Keine laufenden Positionen mehr
Vermögen: - $ am 31.03.2024
Ursprung des Netzwerks ersten Grades von Catarina Edfjäll
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
18
| Public Company | Pharmaceuticals: Major | 18 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Catarina Edfjäll
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
ABBOTT LABORATORIES | Medical Specialties | Chief Tech/Sci/R&D Officer | |
ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
MYRIAD GENETICS, INC. | Medical Specialties | Corporate Officer/Principal | |
AGILE THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
ACHILLION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Aptalis Pharma US, Inc.
Aptalis Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Aptalis Pharma US, Inc. markets pharmaceutical products and services for the treatment of gastrointestinal diseases and disorders. It offers pancrelipase capsules, ursodiol tablets, porfimer sodium for injections, shake mixes, calorie boosters, clearance devices and multivitamin supplements. The firm also provides products for active ulcerative, liver diseases, pancreatic diseases, cystic fibrosis, chronic obstructive pulmonary disease, HIV/AIDS and cancer. The company was founded in 1991 and is headquartered in Wilmington, DE. | Pharmaceuticals: Major | President | |
RHYTHM PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Bath | College/University | Undergraduate Degree | |
BAVARIAN NORDIC A/S | Pharmaceuticals: Major | Director/Board Member | |
SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Director/Board Member | |
Organon NV
Organon NV Pharmaceuticals: MajorHealth Technology N.V. Organon engages in the development, manufacture, and sale of prescription medicines. It offers products for cardiovascular diseases, fertility, gynecology, anesthesia, respiratory, consumer health care, neuroscience as well as immunology, animal health, and oncology. Its products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. The company was founded in 1923 and is headquartered in Oss, the Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Pierre Fabre Médicament SAS
Pierre Fabre Médicament SAS Pharmaceuticals: OtherHealth Technology Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France. | Pharmaceuticals: Other | Chief Tech/Sci/R&D Officer | |
Auburn University | College/University | Masters Business Admin | |
deVGen NV
deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Biotechnology | Corporate Officer/Principal | |
The University of Sheffield | College/University | Undergraduate Degree | |
WEIFA ASA | Pharmaceuticals: Major | Director/Board Member | |
Vrije Universiteit Amsterdam | College/University | Graduate Degree | |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Université Claude Bernard Lyon 1 | College/University | Doctorate Degree | |
École Supérieure de Physique et de Chimie de Paris | College/University | Undergraduate Degree | |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Chairman | |
Harvard Medical School | College/University | Doctorate Degree | |
TA SASU
TA SASU Pharmaceuticals: MajorHealth Technology Aptalis Pharma SAS is engaged in manufacturing pharmaceutical preparations. Its products include zenpep, canasa, carafate, pylera, rectiv, viokace, ultresa lacteol, delursan, panzytrat and salofalk. The company was founded in 1982 and is headquartered in Courbevoie, France. | Pharmaceuticals: Major | Chief Executive Officer | |
Aptalis Holdings, Inc.
Aptalis Holdings, Inc. Pharmaceuticals: MajorHealth Technology Aptalis Holdings Inc. operates as a holding company that develops, manufactures, licenses, markets and distributes therapies for unmet medical needs. It includes cystic fibrosis and gastrointestinal disorders through its subsidiaries. It also formulates and clinically develops enhanced pharmaceutical, biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking and orally disintegration tablet formulations. The company was founded on January 10, 2008 and is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Chief Executive Officer | |
SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chairman | |
Harvard T.H. Chan School of Public Health | College/University | Graduate Degree | |
TREVI THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
LYSOGENE | Miscellaneous Commercial Services | Chairman | |
INTELLIA THERAPEUTICS, INC. | Biotechnology | Chairman | |
KEZAR LIFE SCIENCES, INC. | Biotechnology | Director/Board Member | |
Petra Pharma Corp.
Petra Pharma Corp. Pharmaceuticals: MajorHealth Technology Petra Pharma Corp. operates as a drug development company that develops novel small molecules for the treatment of cancer and metabolic diseases. The company was founded by Lewis Clayton Cantley and Nathanael S. Gray in 2016 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Corporate Officer/Principal | |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Chairman Founder | |
Abcd Ltd. | Director/Board Member | ||
Roche Netherlands BV
Roche Netherlands BV Medical DistributorsDistribution Services Part of Roche Holding AG, Roche Netherlands BV is a Dutch company that wholesales pharmaceuticals and diagnostics products. The private company is based in Woerden, Netherlands. | Medical Distributors | Sales & Marketing | |
Pharm-Olam International LLC
Pharm-Olam International LLC BiotechnologyHealth Technology Pharm-Olam International LLC is a clinical research organization that specializes in providing trial services to pharmaceutical, biotechnology, government, and public health organizations worldwide. Pharm-Olam International is based in Texas and has subsidiaries in the United States. The American company focuses on small molecule therapies and biologics in various areas, including oncology-hematology, rare disease, allergy, autoimmune, infectious disease, and vaccines. Founded in 1994, the private company operates in 60 countries and offers customized solutions for phase I-IV research. | Biotechnology | Director/Board Member | |
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Bavarian Nordic GmbH
Bavarian Nordic GmbH BiotechnologyHealth Technology Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The private company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999. | Biotechnology | Director/Board Member |
Statistik
International
Vereinigte Staaten | 26 |
Vereinigtes Königreich | 7 |
Frankreich | 7 |
Schweiz | 6 |
Niederlande | 3 |
Sektoral
Health Technology | 34 |
Consumer Services | 9 |
Commercial Services | 6 |
Distribution Services | 2 |
Operativ
Director/Board Member | 98 |
Corporate Officer/Principal | 44 |
Independent Dir/Board Member | 39 |
Chief Executive Officer | 15 |
Undergraduate Degree | 13 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Ed Mathers Mathers | 47 |
Anne VanLent | 23 |
Brian O'Callaghan | 20 |
Frank Verwiel | 16 |
Elizabeth Garner | 15 |
Annette Clancy | 10 |
Jacky Vonderscher | 9 |
Ben T. G. Tan | 8 |
Clive Bertram | 8 |
Stephanie Brown | 8 |
Luigi Marro | 7 |
William Brown | 7 |
Jean-Pierre Gotteland | 6 |
David Renas | 6 |
Brandi Howard | 6 |
- Börse
- Insiders
- Catarina Edfjäll
- Unternehmensverbindungen